Contingency analysis of categorised disease activity by DAS28 in patients with RA and PsA pre-COVID-19* and post-COVID-19† vaccination
| Categorised disease activity | Rheumatoid arthritis, n (%) | Psoriatic arthritis, n (%) | ||||
| Prevaccination | Post vaccination | P value‡ | Prevaccination | Post vaccination | P value‡ | |
| Remission (< 2.6) | 225 (37.9) | 251 (42.3) | 0.319 | 120 (47.4) | 129 (51.0) | 0.681 |
| Low (2.6–3.2) | 104 (17.5) | 106 (17.9) | 44 (17.4) | 42 (16.6) | ||
| Moderate (3.2–5.1) | 201 (33.9) | 186 (31.4) | 70 (27.7) | 69 (27.3) | ||
| High activity ≥5.1 | 63 (10.6) | 50 (8.4) | 19 (7.5) | 13 (5.1) | ||
| Total patients | 593 | 593 | 253 | 253 | ||
*The most recent available DAS28 evaluation prior to the date of vaccination (−7.68±6.48 months).
†The most recent available DAS28 evaluation at 3 months post vaccination (2.64±1.68 months).
‡McNemar's test for paired samples.
DAS28, Disease Activity Score in 28 joints.